Biotech | April 29, 2022
Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
For over a decade, AstraZeneca and Plan India’s Young Health Program have been generating awareness and identifying sustainable solutions to influence the behaviour of youths against Non-Communicable Diseases
To extend the nationwide distribution network for the availability of its proprietary & award-winning HPod for corporates & doctors’ clinics, thereby strengthening India’s phygital wellness ecosystem
The plant is expected to start commercial operations from Q4FY24
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Cysoni is a bionic device that paces the heart with real-time respiratory modulation
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Subscribe To Our Newsletter & Stay Updated
